MCID: CSH001
MIFTS: 64

Cushing's Syndrome malady

Categories: Genetic diseases, Rare diseases, Endocrine diseases, Reproductive diseases, Cancer diseases

Aliases & Classifications for Cushing's Syndrome

About this section
Sources:
10Disease Ontology, 45NIH Rare Diseases, 23Genetics Home Reference, 46NINDS, 47Novoseek, 12DISEASES, 51Orphanet, 36MeSH, 24GTR, 35MedlinePlus, 65UMLS, 27ICD10, 29ICD9CM, 42NCIt, 59SNOMED-CT, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Cushing's Syndrome:

Name: Cushing's Syndrome 10 45 46 12 35
Cushing Syndrome 10 45 47 36 65
Cushing Disease 45 23 51 24
Pituitary Corticotroph Micro-Adenoma 45 51
Pituitary-Dependent Cushing Syndrome 45 51
Acth-Secreting Pituitary Adenoma 45 65
Corticotroph Pituitary Adenoma 45 51
Hypercortisolism 45 23
Adrenal Hyperfunction Resulting from Pituitary Acth Excess 45
Pituitary-Dependant Hypercortisolism Disorder 23
Ectopic Adrenocorticotropic Hormone Syndrome 45
Nodular Primary Adrenocortical Dysplasia 45
Pituitary-Dependent Cushing's Disease 65
Pituitary Dependent Cushing Syndrome 45
Pituitary-Dependant Cushing Syndrome 23
 
Pituitary-Dependant Hypercortisolism 23
Pituitary-Dependent Cushings Disease 47
Pituitary Acth Hypersecretion 23
Adrenal Gland Hyperfunction 65
Pituitary Cushing Syndrome 23
Adrenal Cushing's Syndrome 65
Adrenal Cortical Adenoma 65
Suprarenogenic Syndrome 10
Acth Syndrome, Ectopic 65
Adrenal Cortex Adenoma 45
Acth Syndrome Ectopic 47
Ectopic Acth Syndrome 45
Pituitary Basophilism 10
Hyperadrenocorticism 45

Characteristics:

Orphanet epidemiological data:

51
cushing disease:
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: Adult

Classifications:



External Ids:

Disease Ontology10 DOID:12252
ICD1027 E24, E24.9, E24.3
ICD9CM29 255.0
MeSH36 D003480
NCIt42 C2969
Orphanet51 96253
ICD10 via Orphanet28 D35.2, E24.0
MESH via Orphanet37 D047748
UMLS via Orphanet66 C0221406
UMLS65 C0010481, C0342443, C0206667 C0001231, more

Summaries for Cushing's Syndrome

About this section
Genetics Home Reference:23 Cushing disease is caused by elevated levels of a hormone called cortisol, which leads to a wide variety of signs and symptoms. This condition usually occurs in adults between the ages of 20 and 50; however, children may also be affected. The first sign of this condition is usually weight gain around the trunk and in the face. Affected individuals may get stretch marks (striae) on their thighs and abdomen and bruise easily. Individuals with Cushing disease can develop a hump on their upper back caused by abnormal deposits of fat. People with this condition can have muscle weakness, severe tiredness, and progressively thin and brittle bones that are prone to fracture (osteoporosis). They also have a weakened immune system and are at an increased risk of infections. Cushing disease can cause mood disorders such as anxiety, irritability, and depression. This condition can also affect a person's concentration and memory. People with Cushing disease have an increased chance of developing high blood pressure (hypertension) and diabetes. Women with Cushing disease may experience irregular menstruation and have excessive hair growth (hirsutism) on their face, abdomen, and legs. Men with Cushing disease may have erectile dysfunction. Children with Cushing disease typically experience slow growth.

MalaCards based summary: Cushing's Syndrome, also known as cushing syndrome, is related to acth-independent macronodular adrenal hyperplasia and adrenal gland hyperfunction, and has symptoms including round face, thin skin and hypercortisolism. An important gene associated with Cushing's Syndrome is GNAS (GNAS Complex Locus), and among its related pathways are Glucocorticoid Pathway (HPA Axis), Pharmacodynamics and Transcription_CREM signaling in testis. The drugs fludrocortisone and fluorocortisol acetate have been mentioned in the context of this disorder. Affiliated tissues include pituitary, adrenal gland and bone, and related mouse phenotypes are liver/biliary system and endocrine/exocrine gland.

Disease Ontology:10 An adrenal gland hyperfunction that is caused by overactivity of the adrenal cortex caused by a tumor of the pituitary gland.

NIH Rare Diseases:45 Cushing disease is a condition caused by elevated levels of a hormone called cortisol. it is part of a group of diseases known as cushing’s syndrome. the signs and symptoms include weight gain around the trunk and in the face, stretch marks, easy bruising, a hump on the upper back, muscle weakness, tiredness, thin bones that are prone to fracture (osteoporosis), mood disorders and memory problems. patients also have an increased risk of infections, high blood pressure and diabetes. women may have irregular menses and a lot of hair in the body (hirsutism). cushing disease occurs when a benign pituitary tumor (adenoma) or pituitary hyperplasia causes the adrenal glands to produce large amounts of cortisol. the genetic cause of cushing disease is often unknown but some cases are caused by somatic mutations in genes involved in hormonal activity. most cases occur sporadically in people with no family history of the condition. rarely, cushing disease can be inherited, either as an isolated condition or as part of a genetic syndrome (such as multiple endocrine neoplasia type 1 (men1) and familial isolated pituitary adenoma). treatment generally involves surgery to remove the tumor and medications to decrease cortisol levels. last updated: 12/16/2015

MedlinePlus:35 Cushing's syndrome is a hormonal disorder. the cause is long-term exposure to too much cortisol, a hormone that your adrenal gland makes. sometimes, taking synthetic hormone medicine to treat an inflammatory disease leads to cushing's. some kinds of tumors produce a hormone that can cause your body to make too much cortisol. cushing's syndrome is rare. some symptoms are upper body obesity thin arms and legs severe fatigue and muscle weakness high blood pressure high blood sugar easy bruising lab tests can show if you have it and find the cause. your treatment will depend on why you have too much cortisol. if it is because you have been taking synthetic hormones, a lower dose may control your symptoms. if the cause is a tumor, surgery and other therapies may be needed. nih: national institute of diabetes and digestive and kidney diseases

NINDS:46 Cushing's syndrome, also called , is a rare endocrine disorder caused by chronic exposure of the body's tissues to excess levels of cortisol - a hormone naturally produced by the adrenal gland. Exposure to too much cortisol can occur from long-term use of synthetic glucocorticoid hormones to treat inflammatory illnesses. Pituitary adenomas (benign tumors of the pituitary gland) that secrete increased amounts of ACTH ( a substance that controls the release of cortisol) can also spur overproduction of cortisol. Tumors of the adrenal gland and ectopic ACTH syndrome (a condition in which ACTH is produced by various types of potentially malignant tumors that occur in different parts of the body) can cause similar problems with cortisol balance. Common symptoms of Cushing's syndrome include upper body obesity, severe fatigue and muscle weakness, high blood pressure, backache, elevated blood sugar, easy bruising, and bluish-red stretch marks on the skin. In women, there may be increased growth of facial and body hair, and menstrual periods may become irregular or stop completely. Neurological symptoms include difficulties with memory and neuromuscular disorders.

Wikipedia:68 Cushing\'s syndrome is a collection of signs and symptoms due to prolonged exposure to cortisol. Signs... more...

Related Diseases for Cushing's Syndrome

About this section

Diseases in the Cushing's Syndrome family:

Cushing Syndrome, Familial Cushing Syndrome Due to Macronodular Adrenal Hyperplasia
Cushing Syndrome Due to Ectopic Acth Secretion

Diseases related to Cushing's Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 210)
idRelated DiseaseScoreTop Affiliating Genes
1acth-independent macronodular adrenal hyperplasia33.1GNAS, PRKAR1A
2adrenal gland hyperfunction32.0CRH, HSD11B1, POMC, PRL, SST
3cushing syndrome due to ectopic acth secretion12.5
4cushing syndrome due to macronodular adrenal hyperplasia12.4
5cushing syndrome, familial12.3
6pigmented nodular adrenocortical disease, primary, 411.7
7pigmented nodular adrenocortical disease, primary, 311.7
8pigmented nodular adrenocortical disease, primary, 111.6
9pigmented nodular adrenocortical disease, primary, 211.6
10acth-independent macronodular adrenal hyperplasia 211.6
11nelson syndrome10.6
12pulmonary capillary hemangiomatosis10.6ARMC5, GNAS
13acidophil adenoma10.6POMC, SST
14melanoma of soft parts10.6POMC, SST
15primary pigmented nodular adrenocortical disease10.6
16pituitary-dependent cushing's disease10.6
17brain angioma10.5POMC, SST
18free sialic acid storage disorders10.5GH1, GNAS
19tetanic cataract10.5NR3C1, POMC
20acute gonococcal cervicitis10.5CRH, NR3C1
21pituitary adenoma, acth-secreting10.5
22adrenal neuroblastoma10.5GNAS, PRKAR1A, SST
23pseudohypoparathyroidism, type ib10.5ARMC5, GNAS, PDE11A
24villous adenocarcinoma10.5CRH, POMC, SST
25hypoaldosteronism10.5CRH, GH1, POMC
26malignant hyperthermia10.4CRH, NR3C1, POMC
27clear cell renal cell carcinoma10.4CYP21A2, POMC
28glucocorticoid resistance10.4
29malignant acth producing neoplasm of pituitary gland10.4PRL, SST
30spondylocostal dysostosis-anal and genitourinary malformations syndrome10.4CYP21A2, POMC
31pulmonary embolism10.4CRH, POMC, PRL
32hypothalamic neoplasm10.4POMC, PRL
33sensory system cancer10.4POMC, PRKAR1A, PRL
34hyperglobulinemic purpura10.4CRH, NR3C1, POMC
35nodular episcleritis10.4CRH, POMC, PRL
36mixed ductal-endocrine carcinoma10.4POMC, PRL
37cercarial dermatitis10.4POMC, PRL, SST
38congenital coronary artery aneurysm10.4GH1, POMC, PRL
39cranial nerve disease10.4POMC, PRL, SST
40borderline glaucoma10.4HSD11B1, HSD11B2, NR3C1
41orbital granuloma10.3CRH, CYP21A2, POMC
42sella turcica neoplasm10.3POMC, PRL
43hypothryoidism, congenital, nongoitrous 410.3GH1, POMC, PRL
44allergic asthma10.3CRH, POMC, PRL
45spinocerebellar ataxia 2810.3MC2R, POMC
46pituitary adenoma10.3GH1, POMC, PRL
47costocoracoid ligament congenitally short10.3CYP21A2, HSD11B1
48pituitary adenoma, prolactin-secreting10.3GNAS, PRL, SST
49urinary schistosomiasis10.3CRH, POMC, PRL
50molybdenum cofactor deficiency b10.3GH1, POMC, PRL

Graphical network of the top 20 diseases related to Cushing's Syndrome:



Diseases related to cushing's syndrome

Symptoms for Cushing's Syndrome

About this section

Symptoms:

 51 (show all 40)
  • round face
  • thin skin
  • cortico-adrenal hyperplasia/hypersecretion
  • pituitary/hypophyseal neoplasm/tumor/carcinoma/cancer
  • truncal obesity
  • abnormal fat distribution/lipodystrophy
  • failure to thrive/difficulties for feeding in infancy/growth delay
  • cushingoid morphotype
  • acne/acnea
  • hirsutism/hypertrichosis/increased body hair
  • chronic arterial hypertension
  • bruisability
  • urinary/renal lithiasis/kidney stones/nephritic colic
  • metrorrhagia/menorrhagia/hemorrhagic cycles/hyper/poly/spanio/dysmenorrhea
  • sterility/hypofertility
  • diabetes mellitus
  • humour troubles/anxiety/depression/apathy/euphoria/irritability
  • osteoporosis/osteopenia/demineralisation/osteomalacia/rickets
  • mutiple fractures/bone fragility
  • immunodeficiency/increased susceptibility to infections/recurrent infections
  • hypokalemia
  • asthenia/fatigue/weakness
  • cataract/lens opacification
  • visual loss/blindness/amblyopia
  • mild visual loss/impaired visual acuity
  • chronic skin infection/ulcerations/ulcers/cancrum
  • diffuse/generalised skin hyperpigmentation/melanoderma
  • telangiectasiae of the skin
  • onyxis/paronyxis/ungual inflammation
  • epigastralgia/heartburn/gastric/duodenal ulcer/gastritis
  • acute abdominal pain/colic
  • cardiomyopathy/hypertrophic/dilated
  • venous thrombosis/phlebitis/thrombophlebitis
  • precocious menopause/secondary amenorrhea
  • facial pain/cephalalgia/migraine
  • sleep and vigilance disorders
  • obnubilation/coma/lethargia/desorientation
  • psychosis/schizophrenia/maniac disorder
  • myopathy
  • osteonecrosis/bone infarction

HPO human phenotypes related to Cushing's Syndrome:

(show all 34)
id Description Frequency HPO Source Accession
1 round face hallmark (90%) HP:0000311
2 thin skin hallmark (90%) HP:0000963
3 hypercortisolism hallmark (90%) HP:0001578
4 truncal obesity hallmark (90%) HP:0001956
5 abnormality of adipose tissue hallmark (90%) HP:0009124
6 erectile abnormalities hallmark (90%) HP:0100639
7 decreased fertility typical (50%) HP:0000144
8 nephrolithiasis typical (50%) HP:0000787
9 diabetes mellitus typical (50%) HP:0000819
10 hypertension typical (50%) HP:0000822
11 bruising susceptibility typical (50%) HP:0000978
12 hypertrichosis typical (50%) HP:0000998
13 acne typical (50%) HP:0001061
14 striae distensae typical (50%) HP:0001065
15 muscle weakness typical (50%) HP:0001324
16 recurrent fractures typical (50%) HP:0002757
17 hypokalemia typical (50%) HP:0002900
18 reduced bone mineral density typical (50%) HP:0004349
19 cataract occasional (7.5%) HP:0000518
20 secondary amenorrhea occasional (7.5%) HP:0000869
21 hypercortisolism occasional (7.5%) HP:0001578
22 hypertrophic cardiomyopathy occasional (7.5%) HP:0001639
23 abdominal pain occasional (7.5%) HP:0002027
24 sleep disturbance occasional (7.5%) HP:0002360
25 hypercalcemia occasional (7.5%) HP:0003072
26 abnormality of lipid metabolism occasional (7.5%) HP:0003119
27 myopathy occasional (7.5%) HP:0003198
28 hypernatremia occasional (7.5%) HP:0003228
29 abnormality of the gastric mucosa occasional (7.5%) HP:0004295
30 reduced consciousness/confusion occasional (7.5%) HP:0004372
31 aseptic necrosis occasional (7.5%) HP:0010885
32 abnormal renal physiology occasional (7.5%) HP:0012211
33 telangiectasia of the skin occasional (7.5%) HP:0100585
34 neoplasm of the adrenal gland occasional (7.5%) HP:0100631

Drugs & Therapeutics for Cushing's Syndrome

About this section

Drugs for Cushing's Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 112)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Mifepristoneapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 114384371-65-355245
Synonyms:
(11beta,17beta)-11-(4-(Dimethylamino)-phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
(11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one
(11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
(11beta,17beta)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-prop-1-yn-1-ylestra-4,9-dien-3-one
(2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide
(8S,11R,13S,14S,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
(E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide
11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE
11-(4-DIMETHYLAMINO-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodec ahydro-cyclopenta[a]phenanthren-3-one
11beta-(4-(Dimethylamino)phenyl)-17-hydroxy-21-methyl-19-nor-17alpha-pregna-4,9-dien-20-m-3-on
11beta-(4-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-on
11beta-(4-(N,N-Dimethylamino)phenyl)-17alpha-(prop-1-ynyl)-delta4,9-estradiene-17beta-ol-3-one
11beta-(4-Dimethyl-?amino)-?phenyl-17beta-hydroxy-17-(1-propynyl)-?estra-4,9-dien-3-one
11beta-(p-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
122742-25-0
17-beta-Hydroxy-11-beta-(4-dimethylaminophenyl-1)-17-alpha-(prop-1-ynyl)oestra-4,9-dien-3-one
404951-53-7
83203-42-3
84371-65-3
AC1L1IOO
AC1O62SB
Ambap84371-65-3
BIDD:PXR0123
BPBio1_000262
BRD-K37270826-001-04-5
BRN 5779404
BSPBio_000238
C-1073
C07652
C29H35NO2
CHEBI:50692
CHEMBL157
CHEMBL356066
CI-1073
CID55245
CID6445533
CPD000058481
Contragest Brand of Mifepristone
Corlux
D00585
D015735
DB00834
Dacinostat
Danco Brand of Mifepristone
EC-000.2469
EU-0100801
Exelgyn Brand of Mifepristone
FT-0082666
HMS1568L20
HMS2052L05
HMS2090L22
HSCI1_000369
HSDB 6841
I14-11726
Korlym
LAQ-824
LS-192513
LS-64723
Lopac0_000801
M 8046
 
M8046_SIGMA
MLS000069785
MLS001074115
Mifegyne
Mifeprex
Mifeprex (TN)
Mifepriston
Mifepristona
Mifepristona [Spanish]
Mifepristone (USAN/INN)
Mifepristone Contragest Brand
Mifepristone Danco Brand
Mifepristone Exelgyn Brand
Mifepristone [USAN:INN:BAN]
Mifepristonum
Mifepristonum [Latin]
Mifépristone
MolPort-003-849-222
NCGC00025179-05
NCGC00025179-08
NCGC00179632-01
NVP-LAQ 824
NVP-LAQ824
NVP-LAQ824, Dacinostat, LAQ824
Pictovir
Pictovir (TM)
Prestwick0_000299
Prestwick1_000299
Prestwick2_000299
Prestwick3_000299
Prestwick_570
R 38486
R-38486
R38486
RU 38486
RU 486
RU 486-6
RU-38486
RU-486
RU-486, MIFEPRISTONE
RU-486, RU-38486, Mifegyne, Mifeprex, Mifepristone
RU38486
RU486
S1095_Selleck
S1611_Selleck
SAM001246881
SMR000058481
SPBio_002457
Spectrum5_002045
TL8005515
UNII-320T6RNW1F
UNII-V10P524501
VGX-410
VGX-410C
VX-410
ZINC03831128
ZK 98296
ZK-98296
ZK98296
mifepristone
nchembio.313-comp12
2
EpinephrineapprovedPhase 4, Phase 3, Phase 283451-43-45816
Synonyms:
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-dihydroxy-a-[(methylamino)methyl]-Benzyl alcohol
(-)-3,4-dihydroxy-alpha-[(methylamino)methyl]-Benzyl alcohol
(-)-Adrenalin
(-)-Adrenaline
(-)-Epinephrine
(-)-R-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-(−)-adrenaline
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-4-[1-hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
(R)-Adrenaline
(R)-Epinephrine
(−)-adrenaline
02252_FLUKA
1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
1-Adrenalin
1-Epinephrine
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
51-43-4
51-43-4 (FREE BASE)
51028-73-0
A0173
AC-13188
AC1L1L7B
ADR ADRENALINE
ADROP
AI3-19015
Adnephrine
Adrenaclick
Adrenal
Adrenalin
Adrenalin (TN)
Adrenalin in Oil
Adrenalin-Medihaler
Adrenalina
Adrenalina [DCIT]
Adrenaline
Adrenaline (JP15)
Adrenaline/Epinephrine
Adrenalinum
Adrenamine
Adrenan
Adrenapax
Adrenasol
Adrenatrate
Adrenine
Adrenodis
Adrenohorma
Adrenosan
Adrenutol
Adrin
Adrine
Ana-Guard
Ana-Kit
Antiasthmatique
Asmatane Mist
Asthma meter mist
Asthma-nefrin
Asthmahaler Mist
Asthmanefrin
Astmahalin
Astminhal
Auvi-q
BIDD:GT0119
Balmadren
Bernarenin
Biorenine
Bosmin
Brevirenin
Bronkaid
Bronkaid Mist
Bronkaid Suspension Mist
Bupivacaine Hcl and Epinephrine
C00788
CCRIS 4812
CHEBI:28918
CHEMBL679
CID5816
Chelafrin
Citanest Forte
Corisol
D-Epifrin
D-Epinephrine
D00095
DB00668
Drenamist
Dylephrin
Dyspne-Inhal
E4250_SIGMA
EINECS 200-098-7
EPI E Z PEN JR
EPIPEN E Z PEN
EPIPEN JR
Epi EZ Pen Jr
Epifrin
Epiglaufrin
Epinefrin
Epinefrin [Czech]
Epinefrina
Epinefrina [INN-Spanish]
Epinephran
Epinephrin
Epinephrine
Epinephrine (USP)
Epinephrine (USP/INN)
Epinephrine [USAN:INN:JAN]
Epinephrine bitartrate
Epinephrine chloride
Epinephrine hydrochloride
Epinephrinum
Epinephrinum [INN-Latin]
Epipen
Epipen (TN)
Epipen Auto-Injector
Epipen EZ Pen
Epipen Jr
Epipen Jr.
Epipen Jr. Auto-Injector
Epipen jr
Epirenamine
Epirenan
Epirenin
Epitrate
Eppy
 
Esphygmogenina
Exadrin
Glaucon
Glaucosan
Glauposine
Glycirenan
HSCI1_000215
HSDB 4289
Haemostasin
Haemostatin
Hektalin
Hemisine
Hemostasin
Hemostatin
Hypernephrin
Hyporenin
IOP
Intranefrin
Iontocaine
Isoptoepinal
Kidoline
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-Adrenaline Base
L-Epinehphrine
L-Epinephrine
L-Epirenamine
L-Methylaminoethanolcatechol
L-epinephrine
LS-156
Levo-Methylaminoethanolcatechol
Levoadrenaline
Levoepinephrine
Levorenen
Levorenin
Levorenine
Levoreninum
Lopac-E-4642
Lyodrin
Lyophrin
Medihaler-Epi
Metanephrin
Methylaminoethanolcatechol
Methylarterenol
Micronefrin
Micronephrine
MolPort-002-051-368
Mucidrina
Myosthenine
Mytrate
NCGC00015417-01
NCGC00142615-01
NCGC00142615-03
NCGC00142615-04
NCGC00142615-05
NCGC00142615-06
NCGC00142615-07
NSC 62786
NSC62786
Nephridine
Nieraline
PDSP1_001120
PDSP2_001104
Paranephrin
Primatene
Primatene Mist
Primatene Mist Refill
Prime Asthma Relief
R-(-)-Epinephrine
R-Adrenaline
RCRA waste no. P042
Racemic Epinephrine
Racepinephrine
Rcra waste number P042
Renagladin
Renaglandin
Renaglandulin
Renaleptine
Renalina
Renoform
Renostypricin
Renostypticin
Renostyptin
SMP1_000227
ST069368
SUS-PHRINE SULFITE-FREE
Scurenaline
Septocaine
Simplene
Sindrenina
Soladren
Sphygmogenin
Stryptirenal
Styptirenal
Supracapsulin
Supradin
Supranefran
Supranephrane
Supranephrine
Supranol
Suprarenaline
Suprarenin
Suprel
Surenine
Surrenine
Sus-Phrine
Sus-phrine
Susphrine
Sympathin I
Takamina
Takamine
Tokamina
Tonogen
Twinject
Twinject 0.15
Twinject 0.3
Twinject 0.30
UNII-YKH834O4BH
Vaponefrin
Vasoconstrictine
Vasoconstrictor
Vasodrine
Vasoton
Vasotonin
adrenaline
bmse000316
d-Adrenaline
epinephrine
l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
l-Adrenalin
l-Adrenaline
l-Epinephine
l-Epinephrine (synthetic)
l-Epirenamine
l-Methylaminoethanolcatechol
levoepinephrine
nchembio747-comp9
3
ZincapprovedPhase 414777440-66-623994, 32051
Synonyms:
30Zn
Cinc
Zinc
Zinc ion
 
Zincum
Zink
Zn
Zn(ii)
Zn2+
4
LiraglutideapprovedPhase 4278204656-20-2
Synonyms:
204656-20-2
Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
C439759
Liraglutida
Liraglutida [INN-Spanish]
Liraglutide
Liraglutide [USAN:INN]
Liraglutidum
Liraglutidum [INN-Latin]
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide
 
NN 2211
NN-2211
NN2211
NNC 90-1170
N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide
N²⁶-(hexadecanoyl-gamma-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide
Saxenda
UNII-839I73S42A
Victoza
nn 2211
nn2211
victoza
5
MetforminapprovedPhase 4, Phase 2, Phase 31645657-24-9, 1115-70-414219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMBG
DMGG
Diabefagos
Diabetosan
Diabex
Diaformin
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Meguan
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin Hydrochloride
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
Obimet
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
6Contraceptives, OralPhase 4, Phase 3, Phase 1, Phase 23734
7Contraceptives, PostcoitalPhase 4, Phase 3, Phase 1, Phase 2146
8Epinephryl boratePhase 4, Phase 3, Phase 2834
9RacepinephrinePhase 4, Phase 3, Phase 2834
10Contraceptive AgentsPhase 4, Phase 3, Phase 1, Phase 21706
11Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Phase 010002
12HormonesPhase 4, Phase 3, Phase 2, Phase 1, Phase 011748
13Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Phase 09988
14insulinPhase 44278
15Insulin, Globin ZincPhase 44278
16Dipeptidyl-Peptidase IV InhibitorsPhase 4779
17
LactitolPhase 4320585-86-43871
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
 
Floralac
Importal
Oponaf
Portolac
18HIV Protease InhibitorsPhase 44558
19glucocorticoidsPhase 4, Phase 2, Phase 3, Phase 13896
20Hypoglycemic AgentsPhase 4, Phase 2, Phase 34503
21Protease InhibitorsPhase 44558
22Sitagliptin PhosphatePhase 4399
23IncretinsPhase 41326
24
HydrocortisoneapprovedPhase 3, Phase 2, Phase 158350-23-75754, 657311
Synonyms:
(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
1 Hydrocortisone maximum strength
11-Hydrocortisone
11-beta-Hydrocortisone
11-beta-Hydroxycortisone
11a-Hydroxycorticosterone
11alpha-Hydroxycorticosterone
11b,17,21-Trihydroxyprogesterone
11b-Hydrocortisone
11b-Hydroxycortisone
11beta,17,21-Trihydroxyprogesterone
11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
11beta-Hydrocortisone
11beta-Hydroxycortisone
11beta-hydrocortisone
11β-hydrocortisone
17-Hydroxycorticosterone
17a-Hydroxycorticosterone
17alpha-Hydroxycorticosterone
2v95
4-Pregnen-11beta,17alpha,21-triol-3,20-dione
4-Pregnene-11alpha,21-triol 3,20-dione
4-Pregnene-11b,17a,21-triol-3,20-dione
50-23-7
8056-08-4
80562-38-5
8063-42-1
999 Itch Relieving
A-hydrocort
AC-12902
AC1L1L2B
ACETASOL HC
ACETIC ACID W/ HYDROCORTISONE
AI3-25006
AKOS001582651
Acticort
Acticort (TN)
Advanced Hydrocortisone
Aeroseb HC
Aeroseb-HC
Ala-Cort
Ala-Scalp
Alacort
Algicirtis
Alphaderm
Amberin
Anflam
Anti Itch
Anti Itch maximum strength
Anti Itch maximum strength plus
Anti-inflammatory hormone
Anti-itch
Anti-itch Scalp Relief Maximum Strength
Anucort
Anucort-HC
Anusol HC
Anusol HC (TN)
Apres Peel Soothing Balm
Aquacort
Aquanil HC
Atopalm Maximum Strength Anti-itch
Atopalm Moisturizing Hydrocortisone
Aveeno Hydrocortisone Anti Itch
B48448A1-24BA-47CA-8D9E-43E5BC949386
BPBio1_000544
BRD-K93568044-001-03-1
BSPBio_000494
Balneol-hc
Barseb HC
Basan-Corti
Beta-hc
Bio-0648
Bioelements Immediate Comfort Hydrocortisone
Budpak Anti-itch
C00735
C21H30O5
CCRIS 5854
CHEBI:17650
CHEMBL389621
CID5754
COR-OTICIN
CPD000653523
CaldeCORT Spray
Caldecort
Care One Hydrocortisone maximum strength
Cetacort
Chronocort
Cicatricure Ultra Moisturizing
Clear aid
Cleiton
Cobadex
Colocort
Colocort (TN)
Compound F
Compound F (kendall)
Cor-Tar-Quin
Corhydron
Cort-Dome
Cort-Quin
Cortaid 12-hour Advanced Anti-Itch
Cortaid Intensive Therapy Cooling
Cortaid Maximum Strength
Cortanal
Cortef
Cortef (TN)
Cortenema
Cortesal
Corticreme
Cortifair
Cortifan
Cortifoam
Cortiment
Cortisol
Cortisol alcohol
Cortisol, Hydrocortisone
Cortisolonum
Cortisone
Cortisone Cream Intensive Healing
Cortisone Maximum Strength
Cortisone maximum strength
Cortisporin
Cortisporin Otico
Cortispray
Cortizol
Cortizone 10
Cortizone 10 Cooling Cream Anti-itch
Cortizone 10 Cooling Relief
Cortizone 10 Easy Relief
Cortizone 10 Hydratensive Healing Anti Itch
Cortizone 10 Hydratensive Soothing Anti Itch
Cortizone 10 Intensive Healing
Cortizone 10 Intensive Healing Feminine Itch Relief
Cortizone 10 Intensive Healing For Eczema
Cortizone 10 Plus
Cortizone 10 Poison Ivy Relief Pads
Cortolotion
Cortonema
Cortoxide
Cortril
Cremesone
Cremicort-H
Cutisol
Cvs Anti-itch Hydrocortisone
Cvs Cools Itch Fast
Cvs Cortisone
Cvs Pharmacy Anti-itch
Cyclodextrin-encapsulated hydrocortisone
D00088
DB00741
DB07886
Delacort
Derm-Aid
Dermacort
Dermacort Anti-Itch
Dermaquest Skin Therapy Post-skin Resurfacing Balm
Dermarest Eczema Medicated
Dermaspray
Dermil
Dermocortal
Dermolate
Dg Health Hydrocortisone
Dg Health Hydrocortisone Cream Maximum Strength
Dihydrocostisone
Dioderm
Dome-cort
Domolene-HC
Dr. Sheffield Hydrocortisone Anti Itch
Drotic
Duane Reade
Duane Reade hydrocortisone
Duane Reade hydrocortisone plus 12 moisturizers
DuoCort
EINECS 200-020-1
EU-0100594
Ef corlin
Efcorbin
Efcortelan
Efcortelin
Eldecort
Eldercort
Epicort
Epicortisol
Epiderm H
Equaline Anti Itch
Equaline Anti Itch maximum strength
Equate Hydrocortisone
Esiderm H
Evacort
Family Care Hydrocortisone
Family Wellness
Family Wellness Hydrocortisone
Family Wellness Maximum Strength Hydrocortisone
Ficortril
Fiocortril
Fixmyskin Healing Balm Fragrance-free
Fixmyskin Healing Balm Unflavored
Fixmyskin Healing Balm Vanilla Flavor
Fixmyskin Healing Balm Vanilla Fragrance
Flexicort
Foille Insetti
Formu Care Anti Itch maximum strength
Fulton Street Market Anti Itch
Genacort
Genacort (lotion)
Genuine Hydrocortisone
Glycort
Good Neighbor Pharmacy Anti Itch
Good Neighbor Pharmacy Hydrocortisone
Good Neighbor Pharmacy Hydrocortisone Plus 12 Moisturizers
Good Sense Anti Itch
Gyno-Cortisone
H 4001
H-Cort
H-releve Anti-itch
H0135_SIGMA
H0396_SIGMA
H0888_SIGMA
H3160_SIGMA
H4001_SIGMA
H6909_SIGMA
HC
HC #1
HC #4
HC (HYDROCORTISONE)
HMS1569I16
HMS2090M04
HSDB 3339
HYDROCORTISONE AND ACETIC ACID
HYDROCORTISONE IN ABSORBASE
Healerz For Itches
Health Mart Pharmacy Hydrocortisone Maximum Strength Plus 12 Moisturizers
Healthy Accents Cortisone maximum strength
Heb Cort
Heb-Cort
 
Hem-easy Relief Herbal Anti-itch Maximum Itch Relief
Hi-cor
Hidalone
Hidro-Colisona
Hidrocortisona
Hidrocortisona [INN-Spanish]
Hycort
Hycortol
Hycortole
Hydracort
Hydrasson
Hydro Skin
Hydro-Adreson
Hydro-Colisona
Hydro-RX
Hydro-colisona
Hydrocort
Hydrocortal
Hydrocorticosterone
Hydrocortisone
Hydrocortisone (JP15/USP/INN)
Hydrocortisone 1 plus 10
Hydrocortisone Acetate
Hydrocortisone Anti-itch Plus
Hydrocortisone Base
Hydrocortisone Butyrate
Hydrocortisone D
Hydrocortisone HC
Hydrocortisone Intensive Healing Formula
Hydrocortisone Maximum Strength
Hydrocortisone Maximum Strength Plus 12 Moisturizers
Hydrocortisone Plus
Hydrocortisone Plus 12 Moisturizers
Hydrocortisone Probutate
Hydrocortisone Regular Strength
Hydrocortisone Sodium Phosphate
Hydrocortisone Ultra Strength
Hydrocortisone Valerate
Hydrocortisone [INN:BAN:JAN]
Hydrocortisone alcohol
Hydrocortisone anti itch
Hydrocortisone base
Hydrocortisone free alcohol
Hydrocortisone maximum strength
Hydrocortisone solution
Hydrocortisone-Water Soluble
Hydrocortisonum
Hydrocortisonum [INN-Latin]
Hydrocortistab
Hydrocortisyl
Hydrocortone
Hydroskin
Hydroxycortisone
Hysone
Hytisone
Hytone
Hytone (TN)
Hytone lotion
Idrocortisone
Idrocortisone [DCIT]
Incortin-H
Incortin-hydrogen
Intensive Healing Anti Itch
Kaiser Permanente Hydrocortisone
Kendall'S compound F
Kendall's compound F
Kera Hc Hydrocortisone
Kirkland Signature Hydrocortisone Plus maximum strength
Komed HC
Kyypakkaus
LMST02030001
LS-7439
Lacticare HC
Lacticare-HC
Lactisona
Leader Hydrocortisone
Locoid
Loesch Anti-Itch Therapy
Lopac0_000594
Lubricort
Lucky Supersoft MAXIMUM STRENGTH
MLS000069609
MLS001148103
MLS002207135
MLS002222189
Maintasone
Makesense MAXIMUM STRENGTH
Maximum Strength Cortizone 10 Quick Shot 360 Continuous
Maximum Strength Hydrocortisone
Maximum-h
Medicort
Medpride
Meijer Anti Itch
Meijer Anti Itch Cream Plus
Meijer Hydrocortisone
Meijer Hydrocortisone Plus 12 Moisturizers
Members Mark Hydrocortisone
Meusicort
Mildison
Milliderm
MolPort-001-794-637
Monistat Complete Care Instant Itch Relief
NCGC00022848-06
NCGC00022848-07
NCGC00022848-09
NCGC00022848-12
NCI60_000118
NSC 10483
NSC-10483
NSC10483
Natureplex Hydrocortisone Hydro
Neo-Cort-Dome
Neo-Cortef
Neosporin Eczema Essentials Anti Itch
Neosporin-H Ear
Nogenic HC
Nu-derm Tolereen Anti-pruritic
Nutracort
Nystaform-HC
ORLEX HC
Optef
Otalgine
Otic-Neo-Cort-Dome
Otobiotic
Otocort
Otosone-F
Pandel
Pediaderm Hc
Pediotic Suspension
Penecort
Permicort
Piyanping Antiitch
Polcort H
Premier Value Hydrocortisone
Premier Value Hydrocortisone Plus 12 Moisturizers
Preparation H Hydrocortisone
Preparation H Hydrocortisone Cream
Prepcort
Prestwick0_000447
Prestwick1_000447
Prestwick2_000447
Prestwick3_000447
Prestwick_265
Prevex HC
Proactiv Solution Anti-itch Scalp
Procto-pak
Proctocort
Proctocream HC
Proctofoam
Proctosol-hc
Proctozone HC
Procure
Protocort
Publix Hydro
Publix hydro plus
Quadrydern
Quality Choice Hydrocortisone
Quality Choice Hydrocortisone Maximum Strength
Quality Choice Maximum Strength Anti Itch
Racet
Rectasol-HC
Rectoid
Refuge Hc
Reichstein'S substance M
Reichstein's substance M
Remederm HC
Rexall Anti Itch maximum strength relief
Rexall Hydrocortisone 1
Rexall Hydrocortisone plus moisturizers
Rite Aid anti-itch
S1696_Selleck
SAM002264617
SMP1_000156
SMR000059022
SMR000653523
SPBio_002433
Safeway Hydrocortisone Plus 12 Moisturizers
Sanatison
Scalp-Cort
Scalpicin Anti-Itch Maximum Strength
Scalpicin Capilar
Scalpicin Maximum Strength
Scalpicin Scalp Itch Medication Maximum Strength
Schericur
Scheroson F
Shopko Hydrocortisone
Shopko Hydrocortisone Intensive Healing Formula
Shopko Hydrocortisone Maximum Strength
Shopko Hydrocortisone Plus 12 Moisturizers Maximum Strength
Shopko Maximum Strength
Shoprite Hydrocortisone
Sigmacort
Signef
Smart Sense Anti Itch
Smart Sense Anti Itch maximum strength
Smart Sense Hydrocortisone
Solu-cortef
Soothe Rodan Fields
Stie-cort
Stiefcorcil
Sunmark Hydrocortisone
Sunmark Hydrocortisone Plus 12 Moisturizers
Synacort
Systral Hydrocort
Tarcortin
Tecnu Corticool
Texacort
Texacort lotion 25
Thera Plus
Timocort
Topcare Hydrocortisone
Topcare Hydrocortisone Intensive Healing Formula
Topcare Hydrocortisone Plus 12 Moisturizers
Topicort
Transderma H
Traumaide
Truelipids Anti-itch Barrier
U-cort
UNII-WI4X0X7BPJ
UPCMLD-DP133
UPCMLD-DP133:001
Uniderm
Vioform-Hydrocortisone
VoSol HC
Vytone
Walgreens Hydrocortisone Plus 12 Moisturizers
Westcort
Western Family HydroCortisone
Western Family HydroCortisone Plus 12 Moisturizers
Zenoxone
[3H]cortisol
component of Lubricort
component of Neo-Cort-Dome
component of Otalgine
hydrocortisone
25
CabergolineapprovedPhase 3, Phase 24581409-90-754746
Synonyms:
(8R)-6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)Propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide
1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate
1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
81409-90-7
85329-89-1 (diphosphate)
AC-14150
AC1L1HO0
AC1Q5OQ0
BIDD:GT0775
BRD-K86882815-001-01-6
BRN 6020775
C08187
C26H37N5O2
CG-101
CHEBI:3286
 
CHEMBL1201087
CID54746
Cabaser
Cabaser (TN)
Cabaseril
Cabergolina
Cabergolina [Spanish]
Cabergoline
Cabergoline (JAN/USAN/INN)
Cabergoline [USAN:BAN:INN]
Cabergolinum
Cabergolinum [Latin]
D00987
DB00248
Dostinex
Dostinex (TN)
FCE-21336
FT-0081285
Galastop
HMS2090A09
LS-64370
MolPort-003-845-557
Sogilen
UNII-LL60K9J05T
cabergoline
26
DopamineapprovedPhase 3, Phase 2308462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
27
Dexamethasoneapproved, investigationalPhase 3190950-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Baycadron
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
Dexameth
Dexamethansone
 
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone acetate
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone sodium phosphate
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamethsone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
Ozurdex
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
28
MetyraponeapprovedPhase 31154-36-44174
Synonyms:
1,2-Di-3-pyridyl-2-methyl-1-propanone
2-Methyl-1,2-bis(3-pyridyl)-1-propanone
2-Methyl-1,2-di-3-pyridinyl-1-propanone
2-Methyl-1,2-di-3-pyridyl-1-propanone
2-methyl-1,2-dipyridin-3-yl-propan-1-one
2-methyl-1,2-dipyridin-3-ylpropan-1-one
37245-80-0
4885, SU
54-36-4
856525_ALDRICH
AB00513955
AC1L1HKV
AC1Q1LHX
Alliance Brand of Metyrapone
BIDD:PXR0082
BPBio1_000824
BRD-K46862739-001-03-6
BSPBio_000748
C07205
C14H14N2O
CAS-54-36-4
CHEBI:44241
CHEMBL934
CID4174
CPD-7023
CPD000059134
D00410
D008797
DB01011
EINECS 200-206-2
EU-0009322
HMS1570F10
HMS2094I07
HSDB 2500
LS-123097
METOPIRONE (TN)
MLS001066377
MLS001335881
MLS001335882
MYT
 
Mepyrapone
Metapirone
Metapyron
Methapyrapone
Methbipyranone
Methopirapone
Methopyrapone
Methopyrinine
Methopyrone
Metirapona
Metirapona [INN-Spanish]
Metopiron
Metopirone
Metopyrone
Metroprione
Metyrapon
Metyrapone
Metyrapone (JP15/USP/INN)
Metyrapone Alliance Brand
Metyrapone Novartis Brand
Metyrapone [USAN:INN:BAN:JAN]
Metyraponum
Metyraponum [INN-Latin]
MolPort-001-794-644
NCGC00016242-01
NCGC00161837-01
NSC 25265
NSC25265
Novartis Brand of Metyrapone
Prestwick0_000904
Prestwick1_000904
Prestwick2_000904
Prestwick3_000904
SAM002297829
SMR000059134
SPBio_002947
ST51006925
Su 4885
Su-4885
UNII-ZS9KD92H6V
ZINC00001728
metyrapone
29Neurotransmitter AgentsPhase 3, Phase 214795
30Dopamine AgentsPhase 3, Phase 23084
31Dopamine AgonistsPhase 3, Phase 2544
32Hydrocortisone-17-butyratePhase 3, Phase 2, Phase 1583
33Cortisol succinatePhase 3, Phase 2, Phase 1583
34Antiparkinson AgentsPhase 3, Phase 21312
35Adrenocorticotropic HormonePhase 3, Phase 2, Phase 0133
36Hydrocortisone 17-butyrate 21-propionatePhase 3, Phase 2, Phase 1583
37beta-endorphinPhase 3, Phase 299
38Hydrocortisone acetatePhase 3, Phase 2, Phase 1583
39Melanocyte-Stimulating HormonesPhase 3, Phase 298
40EdotreotidePhase 320
41Dexamethasone 21-phosphatePhase 31909
42Dexamethasone acetatePhase 319091177-87-3
43RadiopharmaceuticalsPhase 3, Phase 1, Phase 2362
44BB 1101Phase 31909
45AntimetabolitesPhase 39454
46OrangeNutraceuticalPhase 3217
47
Bexaroteneapproved, investigationalPhase 1, Phase 243153559-49-082146
Synonyms:
153559-49-0
3-methyl-TTNEB
4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid
4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid
4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid
4-[1-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthaleneyl)vinyl]benzene carboxylic acid
9RA
AC1L32UG
BIDD:PXR0021
Bexaroten
Bexarotene
Bexarotene (USAN/INN)
Bexarotene [USAN]
Bexaroteno
Bexarotenum
Bexarotène
C095105
CHEBI:50859
CHEMBL1023
CID82146
D03106
DB00307
Elan brand of bexarotene
 
HMS2089L14
HSDB 7453
I14-1941
LG 1069
LG-100069
LG100069
LG1069
LG69 compound
LGD 1069
LGD-1069
LGD1069
LS-38306
Ligand brand of bexarotene
MolPort-003-845-030
NCGC00181016-01
P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
SBB067189
Targret
Targretin
Targretin (TN)
Targretin-gel
Targretyn
Targrexin
UNII-A61RXM4375
bexaroteno
bexarotenum
p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
p-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl]benzoic acid
48
Gefitinibapproved, investigationalPhase 2330184475-35-2123631
Synonyms:
184475-35-2
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-chloro-4'-Fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
AC-1556
AC1L3X0A
AKOS000280752
BCB03_000781
Bio-0046
C419708
CCRIS 9011
CHEBI:49668
CHEMBL939
CID123631
CU-00000000396-1
D01977
DB00317
DB07998
EC-000.2409
EN002708
FT-0081035
Gefitini
Gefitinib
Gefitinib (JAN/USAN/INN)
Gefitinib [USAN]
Gefitinib, Iressa, ZD1839
HMS2089B19
I01-1227
IRE
 
Iressa
Iressa (TN)
Iressa(TM)
Irressat
K00240
KBioSS_002241
Kinome_3321
Kinome_3322
LS-139916
MolPort-000-883-335
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
NCGC00159455-02
NCGC00159455-03
NSC715055
S1025_Selleck
STK621310
UNII-S65743JHBS
ZD 1839
ZD-1839
ZD-1839, Iressa, Gefitinib
ZD1839
ZINC19632614
gefitinib
nchembio.117-comp18
nchembio866-comp14
49
Octreotideapproved, investigationalPhase 2, Phase 119883150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
 
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Ocphyl
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide acetate
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatin
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
50
Tadalafilapproved, investigationalPhase 2140171596-29-5110635
Synonyms:
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
171596-29-5
1xoz
6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
AC1L380B
ADCIRCA
Acdirca
Adcirca
C429886
CHEBI:41488
CHEMBL779
CID110635
CPD000466321
Cialis
Cialis (TN)
Cialis, GF 196960, IC 351, ICOS 351, Tadalafil
D02008
DB00820
FT-0080116
GF 196960
GF-196960
 
HMS2051N17
HSDB 7303
IC 351
IC-351
ICOS 351
Ic351
KS-1117
LS-186558
LS-187015
LS-187770
Lilly brand of tadalafil
MLS000759426
MLS001165782
MLS001195644
MLS001424132
MolPort-002-885-864
S1512_Selleck
SAM001246586
SMR000466321
Tadalafil
Tadalafil (JAN/USAN/INN)
Tadalafil [USAN]
Tadanafil
UNII-742SXX0ICT
ZINC03993855

Interventional clinical trials:

(show top 50)    (show all 95)
idNameStatusNCT IDPhase
1Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic AdrenalectomyCompletedNCT01959711Phase 4
2Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.RecruitingNCT01794793Phase 4
3Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or AcromegalyRecruitingNCT02060383Phase 4
4Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal HypercortisolismRecruitingNCT01990560Phase 4
5An Extension Study of CORLUX in the Treatment of Endogenous Cushing's SyndromeCompletedNCT00936741Phase 3
6A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's SyndromeCompletedNCT00569582Phase 3
7Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's SyndromeCompletedNCT01371565Phase 3
8Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's DiseaseCompletedNCT00434148Phase 3
9Study of Cabergoline in Treatment of Corticotroph Pituitary TumorCompletedNCT00889525Phase 3
10Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's DiseaseRecruitingNCT02180217Phase 3
11Ga-68-DOTATOC -PET in the Management of Pituitary TumoursRecruitingNCT02419664Phase 3
12Treatment for Endogenous Cushing's SyndromeRecruitingNCT01838551Phase 3
13Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome?RecruitingNCT01504555Phase 3
14Effects of IL-1 Beta on the HPA-axis in Obese PersonsRecruitingNCT02227420Phase 3
15Prevention of Metabolic Complications of Glucocorticoid ExcessRecruitingNCT01319994Phase 2, Phase 3
16An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.Active, not recruitingNCT01582061Phase 3
17Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's DiseaseActive, not recruitingNCT01374906Phase 3
18Efficacy and Safety Evaluation of Osilodrostat in Cushing's DiseaseNot yet recruitingNCT02697734Phase 3
19Effects of Metyrapone in Patients With Endogenous Cushing's SyndromeNot yet recruitingNCT02297945Phase 3
20Mifepristone in Children With Refractory Cushing's DiseaseWithdrawnNCT01925092Phase 3
21Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine OriginCompletedNCT00958841Phase 2
22Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's DiseaseCompletedNCT00171951Phase 2
23A Study to Assess SOM230 in Patients With Pituitary Cushing's DiseaseCompletedNCT00088608Phase 2
24Study of Efficacy and Safety of Osilodrostat in Cushing's SyndromeRecruitingNCT02468193Phase 2
25SOM230 Ectopic ACTH-producing TumorsRecruitingNCT02780882Phase 2
26Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing SyndromeRecruitingNCT02019706Phase 2
27New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing SyndromeRecruitingNCT00001849Phase 1, Phase 2
28Treatment of Cushing's Disease With R-roscovitineRecruitingNCT02160730Phase 2
29Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's DiseaseRecruitingNCT01915303Phase 2
30Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's DiseaseRecruitingNCT02484755Phase 2
31Preoperative Bexarotene Treatment for Cushing's DiseaseRecruitingNCT00845351Phase 1, Phase 2
32Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard TherapyRecruitingNCT00939523Phase 2
33Study of Adrenalectomy Versus Observation for Subclinical HypercortisolismRecruitingNCT02001051Phase 2
34Mifepristone for Metabolic SyndromeRecruitingNCT01419535Phase 1, Phase 2
35Safety and Efficacy of LCI699 in Cushing's Disease Patients.Active, not recruitingNCT01331239Phase 2
36Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical TreatmentNot yet recruitingNCT02713776Phase 2
37Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrsNot yet recruitingNCT02611258Phase 2
38Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) SecretionTerminatedNCT00422201Phase 2
39Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)TerminatedNCT00612066Phase 2
40Pasireotide Therapy in Patients With Nelson's SyndromeTerminatedNCT01617733Phase 2
41Rosiglitazone in Treating Patients With Pituitary TumorsTerminatedNCT00616642Phase 2
42Phase II Study of SOM230 in Patients With Recurrent or Progressive MeningiomaTerminatedNCT00813592Phase 2
43The Factors Associated With the Recurrence in Patients With Cushing DiseaseCompletedNCT02233335
44Cognition, Steroids, and Imaging in Cushings DiseaseCompletedNCT00081341
45Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing SyndromeCompletedNCT00001453
46Examination of Brain Serotonin Receptors in Patients With Mood DisordersCompletedNCT00026832
47Obesity as a Risk Factor for Musculoskeletal Diseases in the U.S. Air Force: Associations and Implications for Force ReadinessCompletedNCT01613001
48Study of Cushing's Syndrome Not Related to ACTH ProductionCompletedNCT00006278
49Hippocampal Complex Volume and Memory Dysfunction in Cushing's SyndromeCompletedNCT00004326
50Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal InsufficiencyCompletedNCT00001180

Search NIH Clinical Center for Cushing's Syndrome

Inferred drug relations via UMLS65/NDF-RT43:


Cochrane evidence based reviews: cushing syndrome

Genetic Tests for Cushing's Syndrome

About this section

Anatomical Context for Cushing's Syndrome

About this section

MalaCards organs/tissues related to Cushing's Syndrome:

33
Pituitary, Adrenal gland, Bone, Skin, Cortex, Adrenal cortex, Testes

Animal Models for Cushing's Syndrome or affiliated genes

About this section

MGI Mouse Phenotypes related to Cushing's Syndrome:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053709.1CRH, GNAS, HSD11B1, NPY, NR3C1, POMC
2MP:00053798.8CRH, GNAS, HSD11B1, MC2R, NR3C1, POMC
3MP:00053678.5CRH, GNAS, HSD11B2, NPY, NR3C1, NR3C2
4MP:00053758.5CRH, GNAS, HSD11B1, MC2R, NPY, NR3C1
5MP:00053858.3GNAS, HSD11B1, HSD11B2, MC2R, NR3C1, NR3C2
6MP:00053867.9CRH, GNAS, HSD11B1, HSD11B2, MC2R, NPY
7MP:00036317.7CRH, GNAS, HSD11B1, MC2R, NPY, NR3C1
8MP:00053787.4CRH, GNAS, HSD11B1, MC2R, NPY, NR3C1
9MP:00053766.8CRH, GNAS, HSD11B1, HSD11B2, MC2R, NPY

Publications for Cushing's Syndrome

About this section

Articles related to Cushing's Syndrome:

(show top 50)    (show all 959)
idTitleAuthorsYear
1
Different patterns of A*80:01:01:01 allele generation based on exon or intron sequences. (25515742)
2015
2
Infertility and Reproductive Function in Patients with Congenital Adrenal Hyperplasia: Pathophysiology, Advances in Management, and Recent Outcomes. (26568487)
2015
3
Endothelin-1 upregulation mediates aging-related cardiac fibrosis. (25584774)
2015
4
Extraskeletal Myxoid Chondrosarcoma Presenting as a Plantar Fibroma: Case Report and Review of the Literature. (26504046)
2015
5
Modulatory effects of brain-derived neurotrophic factor Val66Met polymorphism on prefrontal regions in major depressive disorder. (25745134)
2015
6
Treatment of Chronic Hepatitis C Virus Infection: Some Remaining Obstacles in the United States. (24418358)
2014
7
Proliferative glomerulonephritis associated with monoclonal immune deposits: A case report and review of literature. (25484532)
2014
8
Hepatitis B virus X protein protects hepatoma and hepatic cells from complement-dependent cytotoxicity by up-regulation of CD46. (23391762)
2013
9
Identical human papillomavirus (HPV) genomic variants persist in recurrent respiratory papillomatosis for up to 22 years. (23204170)
2013
10
Evaluation of attention-deficit hyperactivity disorder risk factors. (24319465)
2013
11
The role of SDF-1I+/Rac pathway in the regulation of endothelial progenitor cell polarity; homing and expression of Rac1, Rac2 during endothelial repair. (21964561)
2012
12
Staged hybrid treatment of complex ascending aortic and distal aortic arch pseudoaneurysm after repair of aortic coarctation. (18948867)
2011
13
Widespread cortical lesions on diffusion-weighted imaging in acute portal systemic shunt encephalopathy caused by primary biliary cirrhosis. (21233224)
2011
14
A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancer. (21989022)
2011
15
Inhibitor-bound structures of human pyruvate dehydrogenase kinase 4. (21904029)
2011
16
p.Arg332Cys mutation of NOTCH3 gene in two unrelated Japanese families with CADASIL. (22082899)
2011
17
High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. (19418581)
2009
18
Glucose transporter-1 in pulmonary neuroendocrine carcinomas: expression and survival analysis. (19234439)
2009
19
Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. (19741189)
2009
20
Secretory dynamics of tPA and its modulation by PAI-1 in vascular system. (19483400)
2009
21
Promoter methylation study of the H37/RBM5 tumor suppressor gene from the 3p21.3 human lung cancer tumor suppressor locus. (18038152)
2008
22
Serum retinol binding protein as an indicator of vitamin A status in cirrhotic patients with night blindness. (19568486)
2008
23
A rare case of ectopic adrenocorticotropic hormone syndrome in small cell carcinoma of the vagina: a case report. (18369310)
2008
24
Actimetric evidence that CLOCK 3111 T/C SNP influences sleep and activity patterns in patients affected by bipolar depression. (17221848)
2007
25
Management of acute conjunctivitis in school-aged children. (17410958)
2007
26
UVA photoirradiation of anhydroretinol--formation of singlet oxygen and superoxide. (18717521)
2007
27
Hormonal therapy for male breast cancer: A different approach for a different disease. (16472925)
2006
28
Novel mutations in the PEX2 gene of four unrelated patients with a peroxisome biogenesis disorder. (14630978)
2004
29
Ventricular remodeling in heart failure and the effect of beta-blockade. (15144937)
2004
30
Expression of vascular endothelial growth factor and the adhesion molecule E-cadherin in non-small cell lung cancer. (14981918)
2003
31
Regulation of cell-to-cell communication in non-tumorigenic and malignant human prostate epithelial cells. (11816015)
2002
32
Choroid plexus papilloma in the posterior cranial fossa: MR, CT, and angiographic findings. (11679220)
2001
33
Thin basement membrane nephropathy: a mutation in COL4A5 gene]. (11798584)
2001
34
Sensitivity to change of mobility tests; effect of short term intensive physiotherapy and exercise on spinal, hip, and shoulder measurements in spondyloarthropathy. (10813296)
2000
35
Application of IL-1 beta and 8 mRNA and some other indices in monitoring the activity of ulcerative colitis]. (12567438)
1999
36
Otolaryngologic features of Laurence-Moon-Bardet-Biedl syndrome. (10187963)
1999
37
Simple and defined method to detect the SOD-1 mutants from patients with familial amyotrophic lateral sclerosis by mass spectrometry. (9696308)
1998
38
Alveolar soft part sarcoma: review of nine cases including two cases with unusual histology. (9522219)
1998
39
Modulation of GDP release from transducin by the conserved Glu134-Arg135 sequence in rhodopsin. (8810308)
1996
40
Adrenomedullin, a novel vasoactive hormone, binds to mouse astrocytes and stimulates cyclic AMP production. (8933372)
1996
41
An alternately spliced mRNA encoding functional domains of murine MAdCAM-1. (7488084)
1995
42
Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. (7624378)
1995
43
p53 mutations in flat- and polypoid-type colorectal tumors detected by temperature-gradient gel electrophoresis. (8082516)
1994
44
Desmoplastic trichilemmoma. (1373583)
1992
45
Only multimers of a synthetic peptide of human apolipoprotein E are biologically active. (1869538)
1991
46
Results of surgical treatment of talipes equinovarus congenita. (2805484)
1989
47
Endemic goiter in Greece: nutritional status, growth, and skeletal development of goitrous and non goitrous populations. (4357119)
1973
48
The colon in kwashiorkor. (5565457)
1971
49
Renal hemosiderosis in the hemolytic anemias: diagnosis by means of needle biopsy. (14415802)
1960
50

Variations for Cushing's Syndrome

About this section

Clinvar genetic disease variations for Cushing's Syndrome:

5
id Gene Variation Type Significance SNP ID Assembly Location
1GNASNM_000516.5(GNAS): c.601C> A (p.Arg201Ser)single nucleotide variantPathogenicrs11554273GRCh37Chr 20, 57484420: 57484420

Cosmic variations for Cushing's Syndrome:

7 (show top 50)    (show all 1951)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
2COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
3COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
4COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
5COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
6COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
7COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
8COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
9COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
10COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
11COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
12COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
13COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
14COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
15COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
16COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
17COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
18COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
19COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
20COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
21COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
22COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
23COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
24COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
25COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
26COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
27COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
28COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
29COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
30COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
31COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
32COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
33COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
34COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
35COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
36COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
37COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
38COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
39COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
40COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
41COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
42COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
43COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
44COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
45COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
46COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
47COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
48COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
49COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3
50COSM1684718KCNJ5adrenal gland,adrenal gland,adrenal cortical adenoma,NS3

Expression for genes affiliated with Cushing's Syndrome

About this section
Search GEO for disease gene expression data for Cushing's Syndrome.

Pathways for genes affiliated with Cushing's Syndrome

About this section

Pathways related to Cushing's Syndrome according to GeneCards Suite gene sharing:

(show all 19)
idSuper pathwaysScoreTop Affiliating Genes
110.1CRH, POMC
29.9GNAS, PRKACA, PRKAR1A
39.9GNAS, PRKACA, PRKAR1A
49.9POMC, PRKACA, PRKAR1A
5
Show member pathways
9.8CYP21A2, HSD11B1, HSD11B2
69.8BGLAP, NR3C1, PRKACA
79.8HSD11B1, HSD11B2, PRL
89.7CRH, CYP21A2, GNAS, POMC
9
Show member pathways
9.6CYP21A2, HSD11B1, HSD11B2, POMC
109.6NR3C1, PRKACA, PRKAR1A, SST
119.6BGLAP, GNAS, PRKACA, PRKAR1A
12
Show member pathways
9.5GNAS, PDE8B, PRKACA, PRKAR1A
13
Show member pathways
9.4CYP21A2, GNAS, MC2R, PRKACA
14
Show member pathways
9.3CRH, GH1, GNAS, POMC, PRKACA, PRKAR1A
159.3BGLAP, NR3C1, POMC, PRKACA, PRL
16
Show member pathways
9.3GNAS, MC2R, NPY, PRKACA
179.0CRH, GNAS, MC2R, PDE11A, PDE8B, POMC
18
Show member pathways
8.3CRH, GH1, GNAS, MC2R, NPY, NR3C1
19
Show member pathways
7.1CRH, GH1, GNAS, MC2R, NPY, NR3C1

GO Terms for genes affiliated with Cushing's Syndrome

About this section

Cellular components related to Cushing's Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1ciliary baseGO:009754610.0PRKACA, PRKAR1A

Biological processes related to Cushing's Syndrome according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of JAK-STAT cascadeGO:004642710.4GH1, PRL
2renal water homeostasisGO:000309110.3PRKACA, PRKAR1A
3cellular response to glucagon stimulusGO:007137710.3GNAS, PRKACA, PRKAR1A
4glucocorticoid biosynthetic processGO:000670410.3CRH, HSD11B2
5energy reserve metabolic processGO:000611210.1GNAS, PRKACA, PRKAR1A
6steroid metabolic processGO:00082029.9CRH, HSD11B1, HSD11B2
7hormone-mediated apoptotic signaling pathwayGO:00086289.8CRH, SST
8female pregnancyGO:00075659.8CRH, GNAS, HSD11B2, PRL
9response to drugGO:00424939.4BGLAP, CRH, GNAS, HSD11B2, SST

Molecular functions related to Cushing's Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
13,5-cyclic-AMP phosphodiesterase activityGO:000411510.1PDE11A, PDE8B
2receptor bindingGO:00051029.8CRH, NPY, POMC

Sources for Cushing's Syndrome

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet